Robust recovery in non-COVID-19 business ensures a beat in Q1
04/05/21 -"Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a ..."
Pages
66
Language
English
Published on
04/05/21
You may also be interested by these reports :
12/08/26
Demant reported better-than-expected Q2 results, with robust top-line growth across all segments. Profitability rose by double digits in H1, and ...
12/08/26
Over the past few years, hearing aid firms have disappointed the shareholders who have supported them, resulting in a heavy price being paid. ...
11/08/26
The Q2 results exceeded the street’s expectations, backed by a healthy uptake of newly launched equipment, intra-ocular lenses and dry eye products, ...
06/08/26
Qiagen’s Q2 results exceeded expectations and management’s guidance. Revenue growth was primarily driven by Sample Technologies and Genomics/NGS. ...